Advanced Molecular Imaging - PET/CT

Vereos Digital PET/CT

Proven accuracy inspires confidence

Find similar products

Supported by rigorous clinical evidence, Vereos is the world’s first and only fully digital, clinically proven, PET/CT solution . With proprietary Digital Photon Counting technology for outstanding advances all along the imaging chain, Vereos exemplifies an established total solution to reveal more, earlier, to help you improve patient care and manage costs.

Features
Clinically proven

Clinically proven

Supported by rigorous clinical evidence, with more than four years of investigational studies and over 100 published clinical studies, Vereos delivers the proven accuracy to inspire confidence.
Improved lesion detectability

Improved lesion detectability

While visualization of small lesions is essential for clinicians to diagnose, stage and monitor therapy in oncology patients, in molecular imaging, the challenge is being able to detect these small lesions reliably [1]. Vereos provides improved detectability & characterization of small lesions [2]
Low PET dose

Low PET dose

Dose reduction in PET radiopharmaceutical administration does not have to be a trade-off between radiation exposure and diagnostic image quality. Utilizing appropriate reconstruction algorithms, reduced dose can be administered with no reduction in diagnostic confidence. Vereos provides uncompromised lesion detectability & quantification at 1/2 the PET dose [3]
Fast scans

Fast scans

Fast scanning allows patients to spend less time in the scanner, enhancing the overall patient experience. Vereos provides uncompromised lesion detectability at 1/10 the time [4]
Ready for the future

Ready for the future

With the highest count rate in the industry , Vereos provides enhanced diagnostic confidence with emerging applications that use short half-life tracers.

Pioneering Perspectives: Experiences with the world’s first and only digital PET/CT  

 

 

 

Hear from early adopters of the Vereos digital PET/CT at The Ohio State University Wexner Medical Center about what it means to have a true partner in innovation.

Dr. Michael Knopp, MD, PhD, discusses partnering with Philips and how the Vereos digital PET/CT is a major leap in the advancement of PET imaging.

 

 " I look for a partner that is committed to the innovation we need."

Dr. Jun Zhang, PhD, DABR, shares why he personally believes that the Vereos digital PET/CT system is a game-changer in the field of Nuclear Medicine.

 

"I personally believe (this system) is going to change the world in the field of nuclear medicine."

Katherine Binzel, PhD, shares her overall enthusiasm for the Vereos digital PET/CT and ease of the workflow.

 

 

             "...it is the future of medicine."

  • [1] Nguyen NC,  Image Quality and Diagnostic Performance of a Digital PET Prototype in Patients with Oncologic Diseases: Initial Experience and Comparison with Analog PET, J Nucl Med 2015; 56:1378–1385 [2] Liu X et al, Impact of FDG Dose Reduction on Lesion Quantification in Dynamic PET: A Simulation Study Based on Clinical Trial Data, SNMMI 2016.
  • [2] Liu X et al, Impact of FDG Dose Reduction on Lesion Quantification in Dynamic PET: A Simulation Study Based on Clinical Trial Data, SNMMI 2016.
  • [3] Zhang J., Evaluation of speed of PET acquisition: How fast can we go? - A validation of list mode PET simulation approach with true acquisitions, SNMMI 2017.
  • [4] Zhang J., Evaluation of speed of PET acquisition: How fast can we go? - A validation of list mode PET simulation approach with true acquisitions, SNMMI 2017